Argus Initiates Coverage of DexCom (DXCM) with a Buy Rating

DexCom, Inc. (NASDAQ:DXCM) is one of the best strong buy growth stocks to buy now. On August 21, Argus initiated coverage of DexCom, Inc. (NASDAQ:DXCM) with a Buy rating and $100 price target.

The firm told investors in a research note that it sees DexCom, Inc. (NASDAQ:DXCM) maintaining above industry average growth, leveraging costs to boost profitability, and expanding its customer reach across the continuous glucose monitoring for diabetes landscape.

It added that DexCom, Inc. (NASDAQ:DXCM) has “robust” free cash flows that bolster its balance sheet and allow higher-than-peer research and development investments that drive product innovation.

The firm views the current share levels as an attractive entry point for DexCom, Inc. (NASDAQ: DXCM).

DexCom, Inc. (NASDAQ:DXCM) is a medical device company that manufactures continuous glucose monitoring (CGM) systems to allow real-time health management control. Specializing in diabetes care technology, the company helps improve and simplify diabetes management worldwide.

It offers various medical devices and products, including Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE.

While we acknowledge the potential of DXCM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.